Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cybin Inc. Common Shares (NY:CYBN)

7.940 +0.560 (+7.59%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cybin Inc. Common Shares

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Has Reached Milestone Achievements
Via Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievements
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Spotlighted in “Frontiers in Psychology” Article
Via Investor Brand Network
Takeaways from Benzinga’s Psychedelics Capital Conference
Via Investor Brand Network
Cybin Announces Roster of 28 Expert Faculty and Advisors for its EMBARK Psychedelic Facilitator Training Program
From Cybin Inc.
Via Business Wire
Cybin Announces Publication in Frontiers in Psychology Journal Introducing EMBARK, an Integrative Model of Psychedelic Therapy
From Cybin Inc.
Via Business Wire
Study Discovers Mechanisms Behind Relapse After Treatment of MDD
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Host Webinar Delving into Psychedelics Landscape, Current and Emerging Therapeutics
Via Investor Brand Network
Cybin to Host Key Opinion Leader Webinar on June 9, 2022
From Cybin Inc.
Via Business Wire
Oregon Adopts First Installment of Psilocybin Rules
Via Investor Brand Network
How Your Mental Health May Benefit from a Digital Detox
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain
Via Investor Brand Network
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
From Cybin
Via Business Wire
VC Executive Shares Insights into Legal Psychedelics Landscape
Via Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds
Via Investor Brand Network
CSIRO to Collaborate with Biotechnology Firms on Psychedelic Research
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003
Via Investor Brand Network
Study Finds That Some Mental Disorders Share Genetic Profiles
Via Investor Brand Network
Study Finds Mindfulness, Psychedelic Encounters Beneficial for Mental Well-Being
Via Investor Brand Network
Study Finds Alcohol Cravings Get Stronger After Consumption during Withdrawal
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony
Via Investor Brand Network
Cybin to Participate in NYSE Trading Bell Ceremony on May 18, 2022
From Cybin Inc.
Via Business Wire
Study Indicates People Are Cautious About Psilocybin Therapy, More Awareness Needed
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
Cybin to Present at the H.C. Wainwright Global Investment Conference on May 25, 2022
From Cybin Inc.
Via Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Kernel Share Preliminary Results from Flow Feasibility Study
Via Investor Brand Network
American Billionaire Entrepreneurs Bet Millions on Psychedelics
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – May 10, 2022 – Billionaire Bob Parsons, the founder of GoDaddy, believes psychedelics can heal trauma. The Marine infantryman... 
Via FinancialNewsMedia
U.S. Army Sued Over Discharging Soldiers with Substance-Abuse Issues
Via Investor Brand Network
Topics Lawsuit
Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Proprietary CYB003 Set to Move Forward in First-in-Human Phase 1/2a Clinical Trial
Via Investor Brand Network
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.